The Future of Enterprise Quality Management Software (EQMS) – Part I

by | Aug 17, 2018 | FDA, ISO, Medical Devices, QMS

The future of enterprise quality management software is changing. Quality professionals across the globe are dealing with an astounding number of changes that correspond with new international standards and regulatory requirements, including the transition to ISO 13485:2016, ISO 9001:2015, IATF 16949:2016, as well as the upcoming transition to the new EU Medical Device Regulation (MDR). Additionally, FDA, in the recent Spring Unified Agenda, made it clear that the future goal is to harmonize and modernize regulation of Medical Device Quality Systems. The primary objective is to “reduce compliance and recordkeeping burdens on device manufacturers by harmonizing domestic and international requirements”.

The noted changes in the international regulatory landscape will have a direct impact on quality management system (QMS) design and implementation. Thus, this is an appropriate time to reveal a new approach to QMS thinking and analysis that will undoubtedly pave the way to the future of QMS architecture. With that said, the purpose of this white paper is to introduce some new and innovative concepts that are aimed at taking our current thinking into the future. And yes, this includes incorporating Artificial Intelligence into the design and architecture of a QMS.

In this paper, we will discuss:

  • The history and evolution of quality systems and Enterprise Quality Management Software (EQMS) platforms
  • The concept of a Self-Learning QMS, and the concept of Intelligent EQMS
  • The new QualiMeter tool and the associated unit of measurement (quality process interactions (QPI))
  • The role of artificial intelligence in the future of EQMS platforms.

Get the The Future of Enterprise Quality Management Software Part 1 Whitepaper

Fill out the form below, and the webinar will get sent directly to your inbox.
Carmine Jabri

Carmine Jabri

CEO - As co-founder of E.M.M.A. International Consulting Group, Inc., Carmine Jabri, PhD, MSJ, MSQM, MHA serves as EMMA International’s CEO. Dr. Jabri is an experienced Quality Assurance & Regulatory Affairs professional with more than twenty years of experience implementing, improving, and directing Quality Management Systems and compliance operations. His career includes expertise in the Pharmaceuticals, Medical Device and Biologics industries. Dr. Jabri serves on the Food and Drug Law Institute’s Medical Products committee and is an internationally sought-after quality systems expert. Dr. Jabri holds a Doctor of Philosophy in Epidemiology, a Master of Science in Jurisprudence, a Master of Science in Quality Management, a Master of Science in Health Services Administration, and a Bachelor of Science in Chemistry.

More Resources

Pattern Recognition as a Quality Superpower

Pattern Recognition as a Quality Superpower

There are always new ways and reasons to apply pattern recognition to quality improvement. Better ensuring patient outcomes in health care facilities and improving accuracy for medical diagnoses are two such frontiers.
Record Control for a Regulated World

Record Control for a Regulated World

In a regulated industry, the prevailing posture of regulatory representatives, in my experience, has been “Show me proof.” In fact, the philosophy I’ve heard repeated by regulators is “If it wasn’t documented, it didn’t happen.”
EU MDR SSCP’s: The Importance of Readability

EU MDR SSCP’s: The Importance of Readability

Among many of the new requirements that EU MDR has introduced, the Summary of Safety and Clinical Performance (SSCP) is certainly one of the more confusing ones for many firms. SSCP’s are required for implantable and Class III devices under EU MDR and is intended to be a public document summarizing important safety and clinical performance information about the device.

Ready to learn more about working with us?

Pin It on Pinterest

Share This